Sard Verbinnen & Co. took the top spot across four categories in Mergermarket’s rankings of PR advisors to mergers and acquisitions deals during the first-half of `17.
SVC emerged as the top firm both globally and in the US, measured by both number of transactions and by total value.
Globally, SVC racked up 113 transactions, followed by FTI Consulting with 86, Joele Frank Wilkinson Brimmer Katcher with 77, Brunswick Group with 74 and Kekst with 68.
 |
In terms of value, SVC notched $200 billion, with Brunswick Group at $188 billion, Joele Frank at $151 billion, Kekst at $102 billion and FTI at $99 billion.
US figures told a similar story. SVC was at top in terms of volume, with 101 transactions. Joele Frank recorded 76, Kekst had 62, Abernathy MacGregor had 49 and FTI racked up 35. When measured by dollar value, SVC led at $183 billion, with Joele Frank at $151 billion, Brunswick Group at $110 billion, Kekst at $94 billion and Finsbury at $83 billion.
An Acuris company, Mergermarket employs correspondents across 67 international locations to assemble a comprehensive database of information about the mergers and acquisitions market.
The data for the PR firm rankings measured deals with a value of over $5 million, or deals with an undisclosed value where the target’s turnover exceeds $10 million. If the deal is for a stake of less than 30%, the value must be greater than $100 million.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
